ATE361078T1 - Verwendung von pyridazinone oder phosphinoxid verbindungen zur behandlung der herzarrhythmie - Google Patents

Verwendung von pyridazinone oder phosphinoxid verbindungen zur behandlung der herzarrhythmie

Info

Publication number
ATE361078T1
ATE361078T1 AT97946363T AT97946363T ATE361078T1 AT E361078 T1 ATE361078 T1 AT E361078T1 AT 97946363 T AT97946363 T AT 97946363T AT 97946363 T AT97946363 T AT 97946363T AT E361078 T1 ATE361078 T1 AT E361078T1
Authority
AT
Austria
Prior art keywords
pyridazinone
treatment
phosphine oxide
oxide compounds
arhythmia
Prior art date
Application number
AT97946363T
Other languages
German (de)
English (en)
Inventor
Joseph J Lynch Jr
Joseph J Salata
Richard J Swanson
Bernard Fermini
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE361078T1 publication Critical patent/ATE361078T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT97946363T 1996-10-31 1997-10-29 Verwendung von pyridazinone oder phosphinoxid verbindungen zur behandlung der herzarrhythmie ATE361078T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2934996P 1996-10-31 1996-10-31

Publications (1)

Publication Number Publication Date
ATE361078T1 true ATE361078T1 (de) 2007-05-15

Family

ID=21848595

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97946363T ATE361078T1 (de) 1996-10-31 1997-10-29 Verwendung von pyridazinone oder phosphinoxid verbindungen zur behandlung der herzarrhythmie

Country Status (8)

Country Link
US (3) US5935945A (enExample)
EP (1) EP0946183B1 (enExample)
JP (1) JP2001503413A (enExample)
AT (1) ATE361078T1 (enExample)
AU (1) AU727391B2 (enExample)
CA (1) CA2268922C (enExample)
DE (1) DE69737689T2 (enExample)
WO (1) WO1998018476A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5935945A (en) * 1996-10-31 1999-08-10 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
PT1087934E (pt) * 1998-04-01 2004-07-30 Cardiome Pharma Corp Compostos de eter de aminociclo-hexilo e as suas utilizacoes
US7507545B2 (en) 1999-03-31 2009-03-24 Cardiome Pharma Corp. Ion channel modulating activity method
US6531495B1 (en) 1999-10-02 2003-03-11 Aventis Pharma Deutschland Gmbh 2′-Substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
US7057053B2 (en) * 2000-10-06 2006-06-06 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
US7524879B2 (en) * 2000-10-06 2009-04-28 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
DE10059418A1 (de) 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10060807A1 (de) 2000-12-07 2002-06-20 Aventis Pharma Gmbh Ortho, ortho-substituierte stickstoffhaltige Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10061876A1 (de) 2000-12-12 2002-06-20 Aventis Pharma Gmbh Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10121003A1 (de) 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
US6783979B2 (en) 2001-06-06 2004-08-31 The Trustees Of Columbia University In The City Of New York Research Foundation Of State University Of New York Vectors encoding HCN channels and MiRP1
WO2002098287A2 (en) * 2001-06-06 2002-12-12 The Trustees Of Columbia University In The City Of New York A high throughput biological heart rate monitor that is molecularly determined
DE10128331A1 (de) 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
CA2524323C (en) * 2003-05-02 2012-05-15 Cardiome Pharma Corp. Aminocyclohexyl ether compounds and uses thereof
US20090041841A1 (en) * 2003-05-02 2009-02-12 Cardiome Pharma Corp. Controlled release tablet formulations for the prevention of arrhythmias
US7345086B2 (en) * 2003-05-02 2008-03-18 Cardiome Pharma Corp. Uses of ion channel modulating compounds
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
WO2005018635A2 (en) * 2003-08-07 2005-03-03 Cardiome Pharma Corp. Ion channel modulating activity i
US7345087B2 (en) * 2003-10-31 2008-03-18 Cardiome Pharma Corp. Aminocyclohexyl ether compounds and uses thereof
CA2557085A1 (en) * 2004-02-26 2005-09-09 Merck & Co., Inc. Biological assay
DE102004009931A1 (de) * 2004-02-26 2005-09-15 Aventis Pharma Deutschland Gmbh Kv1.5-Blocker zur selektiven Steigerung der Vorhofkontraktilität und Behandlung der Herzinsuffizienz
US7977373B2 (en) 2004-04-01 2011-07-12 Cardiome Pharma Corp. Prodrugs of ion channel modulating compounds and uses thereof
WO2005097087A2 (en) * 2004-04-01 2005-10-20 Cardiome Pharma Corp. Merged ion channel modulating compounds and uses thereof
US7772232B2 (en) 2004-04-15 2010-08-10 Bristol-Myers Squibb Company Quinazolinyl compounds as inhibitors of potassium channel function
GB0412986D0 (en) 2004-06-10 2004-07-14 Xention Discovery Ltd Compounds
CA2586918C (en) * 2004-11-08 2021-01-19 Cardiome Pharma Corp. Use of ion channel modulating compounds for treating acute atrial fibrillation in a human
US7576212B2 (en) 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
US20060252831A1 (en) * 2005-05-06 2006-11-09 Christopher Offen Method for the treatment of magnesium and potassium deficiencies
US20060252830A1 (en) * 2005-05-06 2006-11-09 Brandon Stephen F Method for the treatment of magnesium and potassium deficiencies
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
GB0815781D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815784D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815782D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB201105659D0 (en) 2011-04-01 2011-05-18 Xention Ltd Compounds
NO3175985T3 (enExample) 2011-07-01 2018-04-28
WO2013112932A1 (en) 2012-01-27 2013-08-01 Gilead Sciences, Inc. Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
EP3206702A1 (en) * 2014-10-16 2017-08-23 Academisch Medisch Centrum Nk3 agonist for use in the treatment of a patient suffering from atrial arrhythmia or fibrillation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8412864D0 (en) * 1984-05-19 1984-06-27 Smith Kline French Lab Chemical compounds
GB8722776D0 (en) * 1987-09-28 1987-11-04 Smith Kline French Lab Chemical compounds
NZ234087A (en) * 1989-06-19 1991-08-27 Teikoku Hormone Mfg Co Ltd 2-(3-aryloxy(2-hydroxy-propylamino))-2-methylpropyl- aminophenyl pyridazine derivatives
US5428031A (en) * 1991-12-03 1995-06-27 Merck & Co., Inc. Methods of treating cardiac arrhythmia
HU214320B (hu) * 1991-12-20 1998-03-02 EGIS Gyógyszergyár Rt. Eljárás új 3(2H)-piridazinon-származékok és ezeket tartalmazó gyógyszerkészítmények előállítására
US5506228A (en) * 1995-02-23 1996-04-09 Merck & Co., Inc. 2,6-diaryl pyridazinones with immunosuppressant activity
US5670504A (en) * 1995-02-23 1997-09-23 Merck & Co. Inc. 2,6-diaryl pyridazinones with immunosuppressant activity
US5935945A (en) * 1996-10-31 1999-08-10 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia

Also Published As

Publication number Publication date
AU5154998A (en) 1998-05-22
DE69737689T2 (de) 2008-01-31
DE69737689D1 (de) 2007-06-14
US5935945A (en) 1999-08-10
US6214810B1 (en) 2001-04-10
CA2268922C (en) 2004-12-28
WO1998018476A1 (en) 1998-05-07
EP0946183B1 (en) 2007-05-02
EP0946183A4 (en) 2001-07-18
JP2001503413A (ja) 2001-03-13
EP0946183A1 (en) 1999-10-06
US6214809B1 (en) 2001-04-10
CA2268922A1 (en) 1998-05-07
AU727391B2 (en) 2000-12-14

Similar Documents

Publication Publication Date Title
ATE361078T1 (de) Verwendung von pyridazinone oder phosphinoxid verbindungen zur behandlung der herzarrhythmie
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE3687069D1 (de) Verwendung von 3'-azido-3'-deoxythymidin zur behandlung oder vorbeugung von menschlichen retrovirus-infektionen.
DE69617235D1 (de) Epoxysteroide aldosteronantagonist und angiotensin ii rezeptor antagonist kombinationstherapie zur behandlung von congestivem herzversagen
DE69738615D1 (de) Verwendung von glp-1 oder analogen zur behandlung von myokardischem infarkt
DE3683318D1 (de) Verwendung von alfuzosin zur behandlung von erkrankungen der harnwege.
DE3677400D1 (de) Verfahren zur behandlung von knochenersatz-implantaten.
ATE362764T1 (de) Methoden zur behandlung der herz arrhythmie
DE3484395D1 (de) Laser zur medizinischen behandlung kranker bereiche organischen gewebes.
DE3788057D1 (de) Verwendung von heterocyclischen Verbindungen zur Behandlung von Depressionen.
DE69526935D1 (de) Verwendung von mycobacterium zur tumorbehandlung
FI841161A7 (fi) Yhdiste ja koostumus terapeuttista tai diagnostista käyttöä varten sekä terapeuttinen hoitomenetelmä.
DE3483330D1 (de) Mittel zur behandlung von erkrankungen der zahnwurzelhaut.
ATE142499T1 (de) Verwendung von kreatinphosphat oder phosphoenolbrenztraubensäure zur behandlung von tumoren
DE69331833D1 (de) Verwendung von vitamin d-glykosiden zur behandlung oder prävention von osteoporose
ATE179594T1 (de) Verwendung von ethisterone zur topischen behandlung von akne oder androgenetischer alopezie
EP1056458A4 (en) PROCESS FOR THE TREATMENT OF PAIN, ESPECIALLY CHRONIC PAIN SPECIFIC TO WOMEN
BG102716A (en) Method for the treatment of cardiac insufficiency by means of formulations opposing the endotheline
EG17822A (en) Direct current(dc)bone growth stimulator for treatment of pseudarthroses
ATE136220T1 (de) Verwendung von bärlauch zur therapie oder prophylaxe von herzrhythmusstörungen
ATE181240T1 (de) Verwendung von somatostatinanalogen zur behandlung von melanomen
DE3875016D1 (de) Therapeutikum zur behandlung von aids.
DE3586420D1 (de) Verwendung von dihydropyridinen zur behandlung und praevention von arteriosklerose.
DE3577550D1 (de) Aminocarbonsaeurekomplexe zur behandlung von knochentumoren.
DE3674321D1 (de) Behandlung geschmeidiger gewebe.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties